Medical-science diagnosis and therapy are conjoining at the molecular stratum to help advance healthcare to new heights. Molecular diagnostics along with the discovery and validation of biomarkers is imperative to fulfilling the potential of personalized healthcare. In the pharma R&D landscape, they are being used to find new therapeutic targets, pinpoint unpromising drug compounds, and locate applicable patient populations for clinical studies. Biomarkers are playing a larger role in delivering significant data for early diagnosis and in terms of disease predisposition, prognosis and the potential of treatment response.
This special report focuses on the market leaders for diagnostics as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of diagnostics prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of diagnostic medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the diagnostics field.